XML 37 R25.htm IDEA: XBRL DOCUMENT v3.26.1
Commitments and Contingencies (Tables)
 3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Clinical Trials

The following is a summary of the Company’s ongoing active contractual clinical trials described below as of March 31, 2026:

  

 

Description of Clinical Trial   Institution   Start Date   Projected End Date   Number of Patients in Trial     Study Objective   Clinical Update   Expected Date of Preliminary Efficacy Signal   NCT No.   Remaining Financial Contractual Commitment  
                                         
LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)   Netherlands Cancer Institute (NKI)   August 2024   December 2026     37     Determine RP2D with atezolizumab   First patient entered August 2024, in total two patients entered   December 2027   NCT06012734     -(1 )
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)   GEIS   June 2023   Enrollment completed September 2024     9 to 18     Determine MTD and RP2D   Fourteen patients
entered		   March 2026   NCT05809830   $ 293,000  
Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)   GEIS   TBD   TBD     150     Determine efficacy: PFS   Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)   TBD   NCT05809830   $ -(1 )
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)   MD Anderson   January 2024   December 2027     42     Determine the OS of patients with recurrent ovarian clear cell carcinoma   Twenty one patients entered   December 2027   NCT06065462     -(1 )
Total                                       $ 293,000  

 

(1)

The Company has no financial contractual commitments associated with these clinical trials at March 31, 2026.